Close this search box.

Science spotlight: New immune evasion pathway, plus BBB breakdown mechanism and more

ARTICLE | Discovery & Translation

BioCentury’s roundup of translational innovations

By Danielle Golovin, Senior Biopharma Analyst

April 20, 2024 12:58 AM UTC

BioTroy Therapeutics Inc. described a new way that tumor cells evade the immune system.

The company, with collaborators from Fudan University, showed in Cell that ITPRIPL1, a membrane protein of previously unknown function, binds and inhibits CD3ɛ on T cells. In mouse models of various solid tumor types, treatment with an anti-ITPRIPL1 antibody promoted T cell infiltration and reduced tumor growth. The antibody also had therapeutic efficacy against naturally occurring tumors in dogs…